96729-80-5

Usage

Structure

A nitrile compound containing a benzene ring with two methoxy groups and a carbonyl group attached to a propanenitrile chain.

Type of compound

Organic compound, nitriles.

Potential applications

Organic synthesis, pharmaceutical research.

Usage

As a building block for the synthesis of various organic compounds, versatile functional group in chemical reactions.

Handling precautions

Potentially hazardous chemical, should be used in a controlled laboratory setting by trained individuals.

Upstream product

• 93-17-4 3,4-dimethoxyphenylacetonitrile 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 18029-59-9 ethyl (2-cyano-2-(3,4-dimethoxyphenyl)vinyl)carbamate 
• 278600-50-3 4-(3,4-dimethoxyphenyl)1H-pyrazol-5-amine 
• 18029-60-2 6,7-dimethoxy-1-oxo-1,2-dihydroisoquinoline-4-carbonitrile 
• 798566-03-7 1-(3-hydroxyethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carbonitrile 
• 798565-46-5 6,7-dimethoxy-1-(3-methylsulfanyl-benzoyl)-isoquinoline-4-carbonitrile 
• 798565-73-8 1-(3-ethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid amide hydrochloride 

Relevant academic research and scientific papers

Efficacy and Tolerability of Pyrazolo[1,5- a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma

RET (REarranged during Transfection) kinase gain-of-function aberrancies have been identified as potential oncogenic drivers in lung adenocarcinoma, along with several other cancer types, prompting the discovery and assessment of selective inhibitors. Internal mining and analysis of relevant kinase data informed the decision to investigate a pyrazolo[1,5-a]pyrimidine scaffold, where subsequent optimization led to the identification of compound WF-47-JS03 (1), a potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays. In subsequent mouse in vivo studies, compound 1 demonstrated effective brain penetration and was found to induce strong regression of RET-driven tumor xenografts at a well-tolerated dose (10 mg/kg, po, qd). Higher doses of 1, however, were poorly tolerated in mice, similar to other pyrazolo[1,5-a]pyrimidine compounds at or near the efficacious dose, and indicative of the narrow therapeutic windows seen with this scaffold.

PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.

Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors

Through high throughput screening and subsequent hit identification and optimization, we synthesized a series of 1-arylcarbonyl-6,7- dimethoxyisoquinoline derivatives as the first reported potent and reversible GFAT inhibitors. SAR studies of this class o

GLUTAMINE FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE (GFAT) INHIBITORS

Compounds of formula (I) are provided, wherein R1 and R2 are as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE

The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.

GFAT INHIBITORS

Compounds of formula (I) are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.